All In Biotech

Drug Trial Radar · NCT07262619

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors, Including Checkpoint Inhibitor Naïve Participants With Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Jan 20, 2026

Primary completion

Mar 2029

Study completion Mar 2029

Sponsor

Lead sponsor
Eikon TherapeuticsIndustry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Dec 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in treating patients with advanced cancer.

Conditions

  • Advanced Solid Tumors
  • MSI-H or dMMR Advanced Solid Tumors
  • MSI-H/dMMR Gastric Cancer
  • MSI-H/dMMR Colorectal Cancer
  • MSI-H/dMMR Gastroesophageal-junction Cancer
  • Endometrial Cancer
  • Mismatch Repair Deficient or MSI-High Solid Tumors

Interventions

  • EIK1005Drug

    EIK1005 is a selective inhibitor of the Werner helicase.

  • pembrolizumab (KEYTRUDA® )Drug

    Pembrolizumab is a PD-1 inhibitor.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-Limiting Toxicity (DLT) - Part 1Time frame: 21 Days
  2. Adverse Events (AEs) - Part 1 and Part 2Time frame: From the time of first dose of study medication through 30 days following cessation of study treatment.

Locations

45 sites in 15 countries. Site status is shown where the registry gives one.

  • California Research Institute (CRI)

    Los Angeles, California · Recruiting

  • Omnicure Clinical Research

    Doral, Florida · Recruiting

  • Bioresearch Partner

    Hialeah, Florida · Recruiting

  • Florida Clinical Trials Group

    Plantation, Florida · Recruiting

  • Florida Clinical Trials Group - Tamarac

    Tamarac, Florida · Recruiting

  • Morristown Medical Center

    Morristown, New Jersey · Recruiting

  • START New York-Long Island

    Lake Success, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center (MSKCC)

    New York, New York · Recruiting

  • START Dallas Fort Worth

    Fort Worth, Texas · Recruiting

  • University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • GenesisCare North Shore (Oncology)

    Saint Leonards, New South Wales, Australia · Not yet recruiting

  • Calvary Mater Newcastle Hospital

    Waratah, New South Wales, Australia · Recruiting

  • Grampians Health

    Ballarat, Victoria, Australia · Recruiting

  • Chris O'Brien Lifehouse (Sydney Cancer Centre)

    Camperdown, Victoria, Australia · Recruiting

  • Oncology Clinics Victoria (OCV) - Cabrini Brighton Hospital

    Frankston, Victoria, Australia · Recruiting

  • Peninsula and Southeast Oncology (PASO) Medical

    Frankston, Victoria, Australia · Recruiting

  • Ordensklinikum Linz Elisabethinen

    Linz, Austria · Recruiting

  • Centre Hospitalier Universitaire Brugmann - Victor Horta

    Brussels, Belgium · Recruiting

  • Kuopio University Hospital

    Kuopio, Finland · Recruiting

  • Hospices Civils De Lyon (hcl) -Centre Hospitalier Lyon-Sud

    Pierre-Bénite, Rhone, France · Recruiting

  • Helios Klinikum Berlin-Buch

    Berlin, Germany · Recruiting

  • Norddeutsches Studienzentrum fur Innovative Onkologie (NIO) Hamatologisch Onkologische Praxis Eppendorf (HOPE)

    Hamburg, Germany · Recruiting

  • DONAUISAR Klinikum

    Deggendorf, Bavaria, Germany · Recruiting

  • Campus Bio-Medico di Rome University

    Rome, Italy · Recruiting

  • Health New Zealand

    Wellington, New Zealand · Recruiting

  • Palmerstone North Hospital

    Roslyn, Manawatu, New Zealand · Recruiting

  • Oslo University

    Oslo, Norway · Recruiting

  • GCPMED Sp. z o.o., Centrum Medyczne iMed24

    Krakow, Poland · Recruiting

  • Centrum Terapii Wspolczesnej J.M. Jasnorzewska Spolka Komandytowo-Akcyjna

    Lodz, Poland · Recruiting

  • One Day Med

    Szczecin, West Pomeranian Voivodeship, Poland · Recruiting

  • Hospital de Santa Maria

    Lisbon, Portugal · Recruiting

  • Unidade Local de Saúde (ULS) Loures Odivelas

    Loures, Portugal · Recruiting

  • Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E. (IPO Porto)

    Porto, Portugal · Recruiting

  • Hospital da Luz Lisboa

    Lisbon, Lisbon District, Portugal · Recruiting

  • National University Hospital (NUH)

    Singapore, Singapore · Recruiting

  • National Cancer Centre Singapore (NCCS)

    Singapore, Central Region, Singapore · Recruiting

  • Korea University Anam Hospital

    Seoul, South Korea · Recruiting

  • Ajou University School of Medicine & Graduate School of Medicine

    Suwon, South Korea · Recruiting

  • Inje University-Haeundae Paik Hospital

    Busan, Busan, South Korea · Recruiting

  • START - Barcelona

    Barcelona, Spain · Recruiting

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.